Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Naphazoline
Accession Number
DB06711
Type
Small Molecule
Groups
Approved, Investigational
Description

Naphazoline is a rapid acting imidazoline sympathomimetic vasoconstrictor of ocular or nasal artierioles6,7. It acts to decrease congestion and is found in many over the counter (OTC) eye drops and nasal preparations6,7.

Naphazoline was first developed in 1942 as a nasal formulation for congestion4.

Structure
Thumb
Synonyms
  • Nafazolin
  • Nafazolina
  • Naphazoline
Product Ingredients
IngredientUNIICASInChI Key
Naphazoline hydrochlorideMZ1131787D550-99-2DJDFFEBSKJCGHC-UHFFFAOYSA-N
Naphazoline nitrateSC99GR1T5S5144-52-5ZAHXYMFVNNUHCP-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NaphconSolution1 mg/1mLOphthalmicAlcon2006-04-20Not applicableUs
VasoconSolution1 mg/1mLOphthalmicCiba Vision2006-08-31Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AK-ConSolution / drops1 mg/1mLOphthalmicPhysicians Total Care, Inc.2000-07-282012-06-30Us
AK-ConSolution / drops1 mg/1mLOphthalmicPreferreed Pharmaceuticals Inc.2005-03-242018-01-23Us
AK-ConSolution1 mg/1mLOphthalmicRebel Distributors1974-08-22Not applicableUs
AlbalonSolution1 mg/1mLOphthalmicAllergan Inc.1984-11-012008-10-21Us
NaphazolineSolution / drops1 mg/1mLOphthalmicPreferreed Pharmaceuticals Inc.2013-04-22Not applicableUs
NaphazolineSolution / drops1 mg/1mLOphthalmicProficient Rx LP1995-12-19Not applicableUs
NaphazolineSolution / drops1 mg/1mLOphthalmicA-S Medication Solutions1995-12-192017-09-30Us
NaphazolineSolution / drops1 mg/1mLOphthalmicAkorn1995-12-192017-09-30Us
NaphazolineSolution / drops1 mg/1mLOphthalmicA S Medication Solutions1995-12-19Not applicableUs
Naphazoline HydrochlorideSolution / drops1 mg/1mLOphthalmicPhysicians Total Care, Inc.1994-05-252009-06-30Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlbalonSolution / drops.1 %OphthalmicAllergan1970-12-31Not applicableCanada
Clear EyesLiquidOphthalmicPrestige Brands Inc2004-03-24Not applicableCanada
Clear Eyes By Murine Eye DpsLiquidOphthalmicAbbott1970-12-312003-10-10Canada
Diopticon Liq 0.1%SolutionOphthalmicPharma Stulln Inc.1994-12-31Not applicableCanada
Naphcon ForteSolutionOphthalmicAlcon, Inc.1977-12-312017-11-13Canada
NazalLiquid50 mg/100mLNasalSato Pharmaceutical Co., Ltd.1990-06-11Not applicableUs
Nazil OftenoSolution / drops0.2 mg/1mLOphthalmicLABORATORIOS SOPHIA, S.A. DE C.V.2010-04-122015-04-29Us
Odan-naphazolineSolutionOphthalmicOdan Laboratories Ltd1986-12-31Not applicableCanada
Opcon Oph Soln 0.1%Solution / dropsOphthalmicBausch & Lomb Inc1987-12-311996-09-09Canada
Opti-tears Red EyeSolutionOphthalmicAlcon, Inc.2017-04-04Not applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
7 Select Redness ReliefNaphazoline hydrochloride (0.00012 mg/1mL) + Glycerin (0.0025 mg/1mL)Solution / dropsOphthalmic7-Select, Inc2017-03-28Not applicableUs
Advanced Eye Relief/ Redness Instant ReliefNaphazoline hydrochloride (0.1 mg/1mL) + Polyethylene glycol 300 (2 mg/1mL)Solution / dropsOphthalmicBauch & Lomb Incorporated2010-09-13Not applicableUs
Advanced Eye Relief/ Redness Maximum ReliefNaphazoline hydrochloride (0.3 mg/1mL) + Hypromellose (5 mg/1mL)Solution / dropsOphthalmicPreferreed Pharmaceuticals Inc.2010-09-02Not applicableUs
Advanced Eye Relief/ Redness Maximum ReliefNaphazoline hydrochloride (0.3 mg/1mL) + Hypromellose (5 mg/1mL)Solution / dropsOphthalmicBauch & Lomb Incorporated2010-09-02Not applicableUs
Albalon ANaphazoline hydrochloride (.05 %) + Antazoline phosphate (.5 %)LiquidOphthalmicAllergan1978-12-312017-07-26Canada
Allergy Eye DropsNaphazoline hydrochloride (0.25 mg/1mL) + Pheniramine maleate (3 mg/1mL)Solution / dropsOphthalmicChain Drug Consortium2014-01-10Not applicableUs
Allergy Eye DropsNaphazoline hydrochloride (0.25 mg/1mL) + Pheniramine maleate (3 mg/1mL)Solution / dropsOphthalmicCVS Health2013-01-25Not applicableUs
Allergy Eye DropsNaphazoline hydrochloride (0.02675 %) + Pheniramine maleate (0.315 %)Solution / dropsOphthalmicBausch & Lomb Inc2013-02-272017-08-03Canada
Blue CollyriumNaphazoline hydrochloride (0.5 mg) + Methylene blue (0.2 mg)LiquidOphthalmicSandoz Canada Incorporated1997-05-132019-08-01Canada
CareOne Maximum Strength Redness ReliefNaphazoline hydrochloride (0.00015 mg/1mL) + Glycerin (0.0025 mg/1mL)Solution / dropsOphthalmicFOODHOLD U.S.A., LLC2017-05-18Not applicableUs
Categories
UNII
H231GF11BV
CAS number
835-31-4
Weight
Average: 210.2744
Monoisotopic: 210.115698458
Chemical Formula
C14H14N2
InChI Key
CNIIGCLFLJGOGP-UHFFFAOYSA-N
InChI
InChI=1S/C14H14N2/c1-2-7-13-11(4-1)5-3-6-12(13)10-14-15-8-9-16-14/h1-7H,8-10H2,(H,15,16)
IUPAC Name
2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole
SMILES
C(C1=NCCN1)C1=CC=CC2=CC=CC=C12

Pharmacology

Indication

Naphazoline is indicated for use as OTC eyedrops for ocular vasoconstriction or as a nasal preparation for nasal congestion1,6,7.

Associated Conditions
Associated Therapies
Pharmacodynamics

Naphazoline is a sympathomimetic alpha adrenergic agonist that acts to vasoconstrict nasal or ocular arterioles, resulting in reduced congestion at the site of administration6,7.

Mechanism of action

Naphazoline is a vasoconstrictor that functions by stimulating alpha adrenergic receptors in arterioles leading to decreased congestion at the site of administration6.

Naphazoline causes the release of norepinephrine in sympathetic nerves3. Norepinephrine binds to alpha adrenergic receptors and causes vasoconstriction3. Naphazoline is also a mild beta adrenergic receptor agonist, which can cause rebound vasodilation after the alpha adrenergic stimulation has ended3. Naphazoline's release of norepinephrine also triggers a negative feedback loop which decreases production of norepinephrine, which can lead to rhinitis medicamentosa after long term use when naphazoline is stopped3.

TargetActionsOrganism
AAlpha-2A adrenergic receptor
agonist
Humans
AAlpha-1A adrenergic receptor
agonist
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Absorption data for naphazoline are scarce but imidazoline compounds in general are weakly basic and lipophilic, with high bioavailability from the gastrointestinal tract5.

Volume of distribution

Distribution data for naphazoline are scarce but imidazoline compounds are distributed throughout the body, and can cross the blood-brain barrier5.

Protein binding

Protein binding data for naphazoline is unavailable8.

Metabolism

Metabolism data for naphazoline are scarce. Imidazoline compounds undergo some hepatic metabolism but a large fraction of the dose may be excreted unchanged in the urine5.

Route of elimination

Imidazoline compounds undergo some hepatic metabolism but a large fraction of the dose may be excreted unchanged in the urine5. Urinary excretion is higher with more acidic urine5.

Half life

Half life has not been determined but effects last for 4 to 8 hours7. Other imidazoline compounds have half lives varying from 2 to 12 hours5.

Clearance

Clearance data for naphazoline is unavailable8.

Toxicity

In high doses or when ingested, naphazoline can lead to central nervous system depression (which can progress to coma and death), hypothermia, bradycardia, and death1. This effect is especially pronounced in children under 6 years1,2.

Long term use of naphazoline can lead to rhinitis medicamentosa once naphazoline is stopped3. This condition is a result of norepinephrine release by naphazoline triggering a negative feedback loop3.

Safety and effectiveness in children under 12 has not been established8. Studies in elderly patients have yet to be performed8. Risk in pregnancy, breast feeding, and on overall fertility have not been established, though pregnant and breast feeding patients should consider the risk and benefit before starting naphazoline treatment8.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic AcidThe risk or severity of hypertension can be increased when 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid is combined with Naphazoline.
1-benzylimidazoleThe risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Naphazoline.
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of hypertension can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Naphazoline.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of hypertension can be increased when Naphazoline is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of hypertension can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Naphazoline.
4-MethoxyamphetamineThe risk or severity of hypertension can be increased when 4-Methoxyamphetamine is combined with Naphazoline.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of hypertension can be increased when Naphazoline is combined with 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleThe risk or severity of CNS depression can be increased when Naphazoline is combined with 7-Nitroindazole.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Naphazoline.
AbediterolThe risk or severity of hypertension can be increased when Naphazoline is combined with Abediterol.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

Synthesis Reference

Roy W. Bryant, Ravi Parihar, Thomas Rowe, Susan Caballa, "Methods of Making and Using Stable Pharmaceutical Compositions Comprising Ketotifen and Naphazoline." U.S. Patent US20110312998, issued December 22, 2011.

US20110312998
General References
  1. Vitezic D, Rozmanic V, Franulovic J, Ahel V, Matesic D: Naphazoline nasal drops intoxication in children. Arh Hig Rada Toksikol. 1994 Mar;45(1):25-9. [PubMed:8067910]
  2. Mahieu LM, Rooman RP, Goossens E: Imidazoline intoxication in children. Eur J Pediatr. 1993 Nov;152(11):944-6. [PubMed:8276031]
  3. Ramey JT, Bailen E, Lockey RF: Rhinitis medicamentosa. J Investig Allergol Clin Immunol. 2006;16(3):148-55. [PubMed:16784007]
  4. HAINSWORTH WC: Accidental poisoning with naphazoline (privine) hydrochloride. Am J Dis Child. 1948 Jan;75(1):76-80. [PubMed:18903384]
  5. Dalefield, Rosalind (2015). 12. In Veterinary Toxicology for Australia and New Zealand (pp. 170-171). Elsevier. [ISBN:978-0-12-420227-6]
  6. Naphazoline Hydrochloride Solution/Drops [Link]
  7. Toxnet: Naphazoline Hydrochloride [Link]
  8. New Zealand Data Sheet: Naphcon-A Eye Drops [File]
External Links
Human Metabolome Database
HMDB0015656
KEGG Drug
D08253
PubChem Compound
4436
PubChem Substance
99443263
ChemSpider
4283
BindingDB
50001922
ChEBI
93363
ChEMBL
CHEMBL761
PharmGKB
PA165958384
Wikipedia
Naphazoline
ATC Codes
R01AB02 — NaphazolineS01GA01 — NaphazolineS01GA51 — Naphazoline, combinationsR01AA08 — Naphazoline
AHFS Codes
  • 52:32.00 — Vasoconstrictors
MSDS
Download (115 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentNeoplasms Malignant1
3CompletedTreatmentAllergic Disorder of Respiratory System / Cold / Flu caused by Influenza1
3CompletedTreatmentConjunctivitis, Seasonal Allergic2
3CompletedTreatmentNasal Congestion / Rhinitis1
4Unknown StatusTreatmentConjunctivitis, Seasonal Allergic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Solution / dropsOphthalmic.1 %
LiquidOphthalmic
LiquidOphthalmic
Solution / dropsOphthalmic
Solution / dropsTopical
Solution / dropsOphthalmic1 mg/1mL
LiquidNasal50 mg/100mL
Solution / dropsOphthalmic0.2 mg/1mL
SolutionOphthalmic
Solution / dropsOphthalmic1 mg/1
SprayNasal0.1 mL/20mL
Suspension / dropsNasal0.125 mL/25mL
SolutionOphthalmic0.1 %
LiquidNasal
Solution / dropsOphthalmic12 mg/100mL
SolutionOphthalmic1 mg/1mL
Solution / dropsOphthalmic
SolutionOphthalmic
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
boiling point (°C)440.466http://www.chemspider.com/Chemical-Structure.4283.html
logP3.881http://www.chemspider.com/Chemical-Structure.4283.html
Predicted Properties
PropertyValueSource
Water Solubility0.0381 mg/mLALOGPS
logP3.44ALOGPS
logP2.19ChemAxon
logS-3.7ALOGPS
pKa (Strongest Basic)10.19ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area24.39 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity65.52 m3·mol-1ChemAxon
Polarizability23.77 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9936
Blood Brain Barrier+0.9693
Caco-2 permeable-0.6307
P-glycoprotein substrateSubstrate0.7448
P-glycoprotein inhibitor INon-inhibitor0.8385
P-glycoprotein inhibitor IINon-inhibitor0.6449
Renal organic cation transporterInhibitor0.8506
CYP450 2C9 substrateNon-substrate0.8202
CYP450 2D6 substrateSubstrate0.7094
CYP450 3A4 substrateNon-substrate0.7297
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.92
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9479
CYP450 3A4 inhibitorNon-inhibitor0.9206
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.889
Ames testNon AMES toxic0.8156
CarcinogenicityNon-carcinogens0.9476
BiodegradationNot ready biodegradable0.9961
Rat acute toxicity2.6904 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7043
hERG inhibition (predictor II)Non-inhibitor0.5354
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0390000000-bf587920984867425a82

Taxonomy

Description
This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthalenes
Sub Class
Not Available
Direct Parent
Naphthalenes
Alternative Parents
Imidolactams / Imidazolines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Carboxamidines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Naphthalene / Imidolactam / 2-imidazoline / Azacycle / Organoheterocyclic compound / Organic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Carboximidamide / Carboxylic acid amidine / Amidine
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Piletz JE, Zhu H, Chikkala DN: Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J Pharmacol Exp Ther. 1996 Nov;279(2):694-702. [PubMed:8930173]
  2. Fukushima H, Norimoto K, Seki T, Nishiguchi T, Nakamura T, Konobu T, Nishio K, Okuchi K: Acute pulmonary edema associated with naphazoline ingestion. Clin Toxicol (Phila). 2008 Mar;46(3):254-6. [PubMed:17852165]
  3. Ogidigben MJ, Chu TC, Potter DE: Naphazoline-induced suppression of aqueous humor pressure and flow: involvement of central and peripheral alpha(2)/I(1) receptors. Exp Eye Res. 2001 Mar;72(3):331-9. [PubMed:11180982]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Bogacka E: [Decongestants in treatment of nasal obstruction]. Otolaryngol Pol. 1999;53(3):347-52. [PubMed:10481510]
  2. Leonardi A: Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20. [PubMed:16083326]
  3. Piletz JE, Zhu H, Chikkala DN: Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J Pharmacol Exp Ther. 1996 Nov;279(2):694-702. [PubMed:8930173]
  4. Hrometz SL, Edelmann SE, McCune DF, Olges JR, Hadley RW, Perez DM, Piascik MT: Expression of multiple alpha1-adrenoceptors on vascular smooth muscle: correlation with the regulation of contraction. J Pharmacol Exp Ther. 1999 Jul;290(1):452-63. [PubMed:10381812]
  5. Kai T: [Effects of topical alpha 1- and beta 2-adrenoceptor stimulants on nasal nitric oxide level]. Nihon Jibiinkoka Gakkai Kaiho. 1999 Jul;102(7):898-906. [PubMed:10459292]
  6. Ogidigben MJ, Chu TC, Potter DE: Naphazoline-induced suppression of aqueous humor pressure and flow: involvement of central and peripheral alpha(2)/I(1) receptors. Exp Eye Res. 2001 Mar;72(3):331-9. [PubMed:11180982]

Drug created on May 16, 2010 11:05 / Updated on November 19, 2019 16:44